Stryker Co. (NYSE:SYK) Shares Bought by Bleakley Financial Group LLC

Bleakley Financial Group LLC boosted its position in shares of Stryker Co. (NYSE:SYK) by 25.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,763 shares of the medical technology company’s stock after buying an additional 1,964 shares during the period. Bleakley Financial Group LLC’s holdings in Stryker were worth $3,515,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Dunhill Financial LLC increased its stake in Stryker by 94.9% during the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after buying an additional 37 shares in the last quarter. Darwin Wealth Management LLC purchased a new stake in Stryker during the 3rd quarter worth approximately $36,000. Crews Bank & Trust purchased a new stake in Stryker during the 4th quarter worth approximately $39,000. Hara Capital LLC purchased a new stake in Stryker during the 3rd quarter worth approximately $42,000. Finally, Grove Bank & Trust increased its stake in Stryker by 84.8% during the 3rd quarter. Grove Bank & Trust now owns 122 shares of the medical technology company’s stock worth $44,000 after buying an additional 56 shares in the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

SYK has been the subject of a number of analyst reports. Evercore ISI upped their price target on Stryker from $380.00 to $384.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. Royal Bank of Canada upped their price target on Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a research report on Wednesday, January 29th. Piper Sandler restated an “overweight” rating and issued a $420.00 price target (up from $380.00) on shares of Stryker in a research report on Wednesday, October 30th. JMP Securities restated a “market perform” rating on shares of Stryker in a research report on Tuesday, January 7th. Finally, JPMorgan Chase & Co. upped their price target on Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. Five analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $419.37.

Stryker Trading Down 0.7 %

SYK opened at $396.24 on Friday. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19. The business has a fifty day simple moving average of $377.08 and a 200-day simple moving average of $364.24. The firm has a market cap of $151.06 billion, a P/E ratio of 51.06, a P/E/G ratio of 2.78 and a beta of 0.96. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter last year, the company earned $3.46 earnings per share. On average, equities analysts expect that Stryker Co. will post 13.5 earnings per share for the current year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a $0.84 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.85%. Stryker’s dividend payout ratio (DPR) is presently 43.30%.

Insider Activity at Stryker

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. The trade was a 5.24 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 5.50% of the stock is currently owned by company insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.